TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34163159
Drug: Ivermectin mucoadhesive
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin mucoadhesive nanosuspension nasal spray twice daily plus Egyptian protocol for mild COVID-19
Study: 34163159
Drug: Ivermectin mucoadhesive
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin mucoadhesive nanosuspension nasal spray
Study: 35144924
Drug: Anifrolumab intensified
Normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab intensified regimen (IR, 900 mg ×3, 300 mg thereafter)
Study: 33944577
Drug: Conidial suspension
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conidial suspension (10^5 ml^-1) from a 15-day-old culture of F. ipomoeae
Study: 32705833
Drug: Ginger-partitioned moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger-partitioned moxibustion applied 2 hours after chemotherapy for 20 min each time, once daily for 3 days
Study: 32705833
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received intravenous injection of Tropisetron (5 mg) 1 h before chemotherapy
Study: 36721509
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg daily for five days
Study: 36721509
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 gram daily and azithromycin 500 mg daily for 5-7 days
Study: 36444879
Drug: Basic body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic body awareness therapy (BBAT) 3 days a week for 6 weeks in addition to a home-based exercise programme
Study: 32353635
Drug: Decision‐Rule Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision‐Rule Based Treatment (DR)
Study: 32353635
Drug: Sequential Treatment
Normalized name: TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Treatment (SEQ)
Study: 32275367
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (electroacupuncture at specified acupoints, continuous wave, 2 Hz, 30 min, 3 times a week for 1 month, 4 courses total)
Study: 33245796
Drug: Evogliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin (5 mg single dose) in patients with mild hepatic impairment
Study: 33245796
Drug: Evogliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin (5 mg single dose) in patients with moderate hepatic impairment
Study: 33245796
Drug: Evogliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin (5 mg single dose)
Study: 32714084
Drug: Intermittent repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent repeated doses of dexamethasone (15 mg total)
Study: 32714084
Drug: One-time 5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time 5-mg dose of dexamethasone
Study: 35941548
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of Magnesium sulphate with steroids
Study: 35941548
Drug: Transforaminal injection
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of Ozone with steroids
Study: 33226116
Drug: Inverse probability
Normalized name: Inversedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse probability of treatment weights (IPTWs)
Study: 32023373
Drug: Lower threshold
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower threshold treatment (glucose concentration <36 mg/dL)
Study: 34719909
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with portable magnet therapy device ALMAG+ (Almag Active)
Study: 36350354
Drug: Model-informed precision
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin
Study: 36350354
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of beta-lactam antibiotics and ciprofloxacin
Study: 36795232
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment
Study: 35143022
Drug: Baseline comorbidities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline comorbidities and treatments
Study: 35143022
Drug: Drugs increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs increasing risk
Study: 37261907
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI)
Study: 32357128
Drug: Telerehabilitation-based McKenzie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation-based McKenzie therapy (TBMT)
Study: 32357128
Drug: Clinic-based McKenzie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based McKenzie therapy (CBMT)
Study: 33591324
Drug: RW-CHOP (CHOP-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg/m2])
Study: 33591324
Drug: R-CHOP (CHOP-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg/m2])
Study: 33034180
Drug: Vacuum-gradient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-gradient therapy combined with orthodontic correction (n=29)
Study: 36071424
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment
Study: 37500339
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg every 3 weeks)
Study: 34326048
Drug: 0.05% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% potassium permanganate (KMnO4) solution
Study: 34326048
Drug: 5% tea
Normalized name: IODINE 5 g in 1 L TOPICAL SOLUTION [DariSoft .5% Teat Dip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% tea tree oil (TTO) gel
Study: 33122343
Drug: Neoadjuvant anti-HER2
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant anti-HER2 therapy
Study: 35140313
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU of vitamin D3 taken daily
Study: 35064366
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) at 8 AM, 1 PM, and placebo at 8 PM
Study: 35064366
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) at 8 AM, 1 PM, and 8 PM (Control)
Study: 34542190
Drug: Antioxidants and
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants and zinc combination
Study: 38952884
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 doses)
Study: 37919141
Drug: mRNA-1273 (Spikevax®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (Spikevax®, 100 µg)
Study: 36016478
Drug: Local ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local ibuprofen (Odontocide)
Study: 36016478
Drug: Systemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic ibuprofen (Ultracal + 200 mg ibuprofen)
Study: 36164019
Drug: P1101 (ropeginterferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1101 (ropeginterferon Alfa-2b) administered subcutaneously every 2 weeks at starting dose of 250 mcg (Week 0), 350 mcg (Week 2), and target dose of 500 mcg (Week 4) for the remainder of the treatment period.
Study: 36348617
Drug: Clade C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clade C regimen (adenovirus 26-based HIV-1 vaccine encoding 2 mosaic Gag and Pol, and 2 mosaic Env proteins plus adjuvanted clade C gp140)
Study: 35013548
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care medical treatment
Study: 36307956
Drug: Moderate-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-protein diet with 25 g beef/d (B25, n=45)
Study: 35120546
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy program
Study: 33602603
Drug: Biotène Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotène Moisturizing Spray (3 sprays)
Study: 34310874
Drug: Electrochemotherapy (ECT)
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemotherapy (ECT) with intravenous and intratumoral administration of bleomycin
Study: 33027362
Drug: Cefazolin (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (antibiotic group)
Study: 35822425
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ACEi)
Study: 34495579
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of fresh table grape per kg of body weight for 21 days
Study: 33720637
Drug: Donanemab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donanemab (700 mg for the first three doses and 1400 mg thereafter)
Study: 35241182
Drug: General form
Approvals — FDA: no, EMA: no, PMDA: no
Description: General form of CBT treatment
Study: 36453313
Drug: Subconjunctival MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival MMC injection at the end of trabeculectomy
Study: 36453313
Drug: IntraTenon MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IntraTenon MMC injection before the initial conjunctival incision
Study: 34624174
Drug: FDC tablets
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablets of macitentan/tadalafil (10/40 mg)
Study: 35151971
Drug: Amitriptyline (AMT)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AMT) 25 mg every night
Study: 33630912
Drug: Retina fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retina fraction dose
Study: 35665493
Drug: Distraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction therapy
Study: 33017120
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo treatment)
Study: 34862248
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy (200 mg IV every 3 weeks)
Study: 34862248
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + Acalabrutinib (100 mg orally twice daily)
Study: 34592684
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylphenidate (N=13)
Study: 34592684
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine (N=14)
Study: 36134902
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneously q6 months)
Study: 34322673
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg BID for 10 days
Study: 34903538
Drug: Chlorhexidine oral
Normalized name: chlorhexidine Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine oral rinses (0.12%)
Study: 36167367
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous iron and tranexamic acid
Study: 32609576
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (C, L, L + P)
Study: 33507774
Drug: ACCESS (cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCESS (cognitive-behavioral therapy program)
Study: 32726556
Drug: Multiple punctures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple punctures injection technique of incobotulinumtoxin A (IncoA; Xeomin)
Study: 32726556
Drug: Radial injection
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial injection technique of incobotulinumtoxin A (IncoA; Xeomin)
Study: 35454318
Drug: Repeated injection
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injection of 2 mL of 1% lidocaine (three injections; one injection per week)
Study: 35454318
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) (three treatment sessions; one treatment session per week; 2000 radial extracorporeal shock waves per treatment session; positive energy flux density = 0.10 mJ/mm2)
Study: 36490292
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) intervention, average of 12 sessions
Study: 36490292
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) intervention
Study: 34645660
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and short intervention
Study: 35916290
Drug: Secukinumab 300mg
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 300mg with loading dose
Study: 35916290
Drug: Secukinumab 150mg
Normalized name: SECUKINUMAB 150MG/ML INJ,SYR,1ML
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 150mg without loading dose
Study: 32465000
Drug: Riociguat (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (up to 2.5 mg tid)
Study: 33615843
Drug: Unblinded nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblinded nitroglycerin infusion at 0.5 µg/kg/min for 20 minutes
Study: 33615843
Drug: Unblinded nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblinded nitroglycerin infusion
Study: 33615843
Drug: Single-blinded nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blinded nitroglycerin infusion
Study: 33615843
Drug: Single-blinded placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blinded placebo infusion
Study: 33933059
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (360 μg MK-7 daily for 12 weeks)
Study: 32118347
Drug: Patient-managed (nurse-assisted)
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-managed (nurse-assisted) titration of Gla-300
Study: 34420049
Drug: Dispersible paediatric
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible paediatric fixed dose combination (FDC) tablets delivering higher doses of first‐line antituberculosis drugs (rifampicin/isoniazid/pyrazinamide 75/50/150 mg, with or without 100 mg ethambutol, or rifampicin/isoniazid 75/50 mg)
Study: 34420049
Drug: Recommended weight-band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended weight-band based FDC doses
Study: 34420049
Drug: Ethambutol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol at current WHO-recommended doses
Study: 33906450
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy
Study: 34551215
Drug: iGlarLixi +
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi + insulin glulisine
Study: 33040383
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injection therapy
Study: 34619438
Drug: ND0612 (levodopa/carbidopa)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND0612 (levodopa/carbidopa) infusion
Study: 34619438
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion + standard of care (SoC)
Study: 35550468
Drug: Sinomenine (zhengqing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinomenine (zhengqing fengtongning sustained-release tablets) administered for 12 weeks.
Study: 35550468
Drug: Colchicine placebo
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine placebo administered for 12 weeks along with febuxostat (40 mg/d) and anti-inflammatory prophylaxis therapy.
Study: 35550468
Drug: Colchicine administered
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine administered for 12 weeks.
Study: 32966919
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (300 IU/kg up to a maximum of 6000 IU daily)
Study: 36305511
Drug: Scheduled acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled acetaminophen, gabapentin, ketorolac, and as-needed opioids (Experimental group)
Study: 36305511
Drug: Scheduled acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled acetaminophen and as-needed opioids (Control group)
Study: 34538072
Drug: Adavosertib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (250 mg or 300 mg)
Study: 35439303
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg daily for an intended duration of 3 months
Study: 33234138
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy for women > 50 years
Study: 33234138
Drug: No estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No estradiol therapy for women > 50 years
Study: 33026490
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (8 weekly sessions of 60 min each)
Study: 36417955
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion of RBCs sufficient to raise hemoglobin to at least 10 g/dL)
Study: 36417955
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusion of RBCs if hemoglobin falls below 8 g/dL or for persistent angina despite medical therapy)
Study: 33430476
Drug: Ai Chi
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ai Chi aquatic therapy
Study: 32630188
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (alternating dry-land therapy and Ai Chi aquatic therapy)
Study: 32630188
Drug: Dry-land therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry-land therapy (control group)
Study: 33023894
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks
Study: 33023894
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with sodium nitrite and isoquercetin
Study: 33109661
Drug: Nebuliser with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuliser with data recording and transfer capability, linked to a software platform, and strategies to support adherence to nebulised treatments facilitated by interventionists over 5 months (+/‐ 1 month)
Study: 32487250
Drug: PST-IPV (Problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST-IPV (Problem Solving Therapy tailored for IPV)
Study: 32487250
Drug: Standard PST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PST (Problem Solving Therapy)
Study: 35277034
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg body mass)
Study: 35141484
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) - 25 patients, 3 sessions (once per week, 1.8 bar pneumatic pressure, 10 Hz frequency, 2,000 pulses)
Study: 38103144
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy
Study: 36351465
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg daily
Study: 35307033
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus rosuvastatin 5 mg daily
Study: 38796500
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics
Study: 32782010
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day thylakoid
Study: 32986105
Drug: Targeted gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted gene testing (TGT) and tailored first-line therapy
Study: 32986105
Drug: Empirical imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical imatinib therapy
Study: 33150170
Drug: Moisturizer containing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer containing licochalcone A, 1,2‐decanediol, L‐carnitine, and salicylic acid applied twice a day for 12 weeks
Study: 33150170
Drug: Vehicle moisturizer
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle moisturizer applied twice a day for 12 weeks
Study: 34006498
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy (Cohort C)
Study: 34006498
Drug: Pazopanib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib monotherapy (Cohort C)
Study: 35236276
Drug: SEP-227900 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-227900 (80 mg)
Study: 38282503
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.25% bupivacaine
Study: 34606378
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg plus rituximab